GRI Bio, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GRI Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for inflammatory, fibrotic, and autoimmune conditions across the United States. Its robust pipeline features several promising candidates, including GRI-0621, which is currently in Phase 2a clinical development, targeting severe fibrotic lung diseases such as idiopathic pulmonary fibrosis. Another key asset, GRI-0803, is in preclinical stages, with plans for Phase 1 trials focusing on autoimmune disorders like systemic lupus erythematosus. The company also maintains a substantial library of over 500 proprietary compounds aimed at modulating Natural Killer T (NKT) cells, which are crucial regulators early in the inflammatory cascade, to restore immune system balance. Earlier in 2023, the entity, formerly known as Glycoregimmune, Inc., completed a merger that significantly advanced its NKT cell modulator pipeline. GRI Bio, Inc. was established in 2009 and operates from its headquarters in La Jolla, California.
Company News
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
GRI Bio Featured in "Why Now" On-Demand Video Webcast
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks
Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact
Ingram Micro Releases 2025 Sustainable Impact Report
Williams Improves on Key Sustainability Metrics Amid Rising Energy Demand
Banner Bank Releases New Corporate Responsibility Report
Asbury Automotive Group Named in TIME America's Best Companies 2026 List
Luxshare Precision Releases 2025 Sustainability Report
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TOWARD 2030 GOALS
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
The Toro Company Publishes 2025 Global Sustainability Impact Report
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline